Yasuharu Kashiwagura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasuharu Kashiwagura has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Shimako Tanaka
Department of Pharmacy Practice and Science , School of Pharmaceutical Sciences University of Shizuoka ; 52–1 Yada Suruga-ku, Shizuoka 422–8526 , Japan
3 shared publicationsAkio Hakamata
Fujimi Kodomo Clinic
2 shared publicationsNoriyuki Namiki
Department of Pharmacy Practice and Science , School of Pharmaceutical Sciences University of Shizuoka ; 52–1 Yada Suruga-ku, Shizuoka 422–8526 , Japan
2 shared publications- Shinya Uchida
Departments of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
2 shared publications Akira Endoh
Pediatrics, Iwata City Hospital
1 shared publicationHidehito Takano
Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences University of Shizuoka
1 shared publication
Latest Publications
- Open Access
- 28 January 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (2) , e70111
Development and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin‐Induced Nephrotoxicity
Background: Vancomycin (VCM), a first‐line treatment option for infections caused by methicillin‐resistant Staphylococcus aureus , has been reported to cause nephrotoxicity even within therapeutic concentration ranges. Traditional therapeutic drug monitoring strategies rely primarily on the area under the concentration–time curve (AUC), without adequately accounting for multiple clinical risk factors associated with nephrotoxicity. Objective: The present study aimed to develop a novel scoring model that integrates clinical risk factors and pharmacokinetic parameters to predict VCM‐induced nephrotoxicity and validate its predictive performance. Methods: We conducted a single‐center retrospective cohort study on patients who received VCM therapy between April 2021 and March 2023. A multivariable logistic regression analysis was performed to identify independent risk factors for VCM‐induced nephrotoxicity, and regression coefficients were used to construct the scoring model. The predictive performance of the proposed model was compared with a conventional AUC‐based model using the area under the receiver operating characteristic curve (ROC AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: The scoring model consisted of the following components: the steady‐state area under the concentration–time curve (0–8 points), the concomitant use of tazobactam/piperacillin (2 points), the use of loop diuretics (1 point), and the presence of chronic liver disease (2 points). The proposed model demonstrated high predictive performance, with ROC AUC values of 0.79 (95% confidence interval [CI]: 0.71–0.87) in the derivation cohort and 0.84 (95% CI: 0.72–0.96) in the validation cohort. Furthermore, the proposed model showed significantly better performance than the conventional model in terms of NRI (derivation cohort: 0.78, 95% CI: 0.47–1.08; validation cohort: 1.23, 95% CI: 0.79–1.67) and IDI (derivation cohort: 0.07, 95% CI: 0.04–0.11; validation cohort: 0.27, 95% CI: 0.15–0.39) ( p < 0.001). Conclusion: The scoring model developed in the present study may enhance risk stratification for VCM‐induced nephrotoxicity and contribute to advances in individualized dosing strategies in clinical practice.
- 28 January 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (2) , e70111
Open AccessDevelopment and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin‐Induced Nephrotoxicity
Background: Vancomycin (VCM), a first‐line treatment option for infections caused by methicillin‐resistant Staphylococcus aureus , has been reported to cause nephrotoxicity even within therapeutic concentration ranges. Traditional therapeutic drug monitoring strategies rely primarily on the area under the concentration–time curve (AUC), without adequately accounting for multiple clinical risk factors associated with nephrotoxicity. Objective: The present study aimed to develop a novel scoring model that integrates clinical risk factors and pharmacokinetic parameters to predict VCM‐induced nephrotoxicity and validate its predictive performance. Methods: We conducted a single‐center retrospective cohort study on patients who received VCM therapy between April 2021 and March 2023. A multivariable logistic regression analysis was performed to identify independent risk factors for VCM‐induced nephrotoxicity, and regression coefficients were used to construct the scoring model. The predictive performance of the proposed model was compared with a conventional AUC‐based model using the area under the receiver operating characteristic curve (ROC AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: The scoring model consisted of the following components: the steady‐state area under the concentration–time curve (0–8 points), the concomitant use of tazobactam/piperacillin (2 points), the use of loop diuretics (1 point), and the presence of chronic liver disease (2 points). The proposed model demonstrated high predictive performance, with ROC AUC values of 0.79 (95% confidence interval [CI]: 0.71–0.87) in the derivation cohort and 0.84 (95% CI: 0.72–0.96) in the validation cohort. Furthermore, the proposed model showed significantly better performance than the conventional model in terms of NRI (derivation cohort: 0.78, 95% CI: 0.47–1.08; validation cohort: 1.23, 95% CI: 0.79–1.67) and IDI (derivation cohort: 0.07, 95% CI: 0.04–0.11; validation cohort: 0.27, 95% CI: 0.15–0.39) ( p < 0.001). Conclusion: The scoring model developed in the present study may enhance risk stratification for VCM‐induced nephrotoxicity and contribute to advances in individualized dosing strategies in clinical practice.
- Open Access
- 24 January 2023
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 73 (1) , 107-119
Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods
This study aimed to elucidate the characteristics and pharmacokinetics of orally disintegrating tablets (ODTs) containing coenzyme Q10 (CoQ10) granules prepared by spray drying, hot-melting, and wet granulation. The hardness and disintegration times of CoQ10-ODTs containing 5 % crospovidone were 61.6–81.8 N and < 30 s, respectively; these values indicate that the as-prepared ODTs were adequate for clinical use. The hardness and disintegration times of all ODTs did not change significantly after a 28-day storage period at 30 °C/10 % relative humidity (RH), but storage under high temperature and humidity affected their characteristics. The dissolution and pharmacokinetics of CoQ10-ODTs showed that ODTs prepared using the spray-drying method had the highest dissolution and absorbability among the CoQ10-ODTs tested. These results provide useful information for the preparation of ODTs using CoQ10.
- 24 January 2023
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 73 (1) , 107-119
Open AccessTablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods
This study aimed to elucidate the characteristics and pharmacokinetics of orally disintegrating tablets (ODTs) containing coenzyme Q10 (CoQ10) granules prepared by spray drying, hot-melting, and wet granulation. The hardness and disintegration times of CoQ10-ODTs containing 5 % crospovidone were 61.6–81.8 N and < 30 s, respectively; these values indicate that the as-prepared ODTs were adequate for clinical use. The hardness and disintegration times of all ODTs did not change significantly after a 28-day storage period at 30 °C/10 % relative humidity (RH), but storage under high temperature and humidity affected their characteristics. The dissolution and pharmacokinetics of CoQ10-ODTs showed that ODTs prepared using the spray-drying method had the highest dissolution and absorbability among the CoQ10-ODTs tested. These results provide useful information for the preparation of ODTs using CoQ10.
- 1 April 2022
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 70 (4) , 277-282
Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream
Propranolol is used as the first-line treatment for infantile hemangiomas (IHs). As oral formulations can cause systemic adverse drug reactions (ADRs), we prepared topical propranolol formulations and evaluated their pharmaceutical profiles. We also present three cases of pediatric patients with IHs who were treated with the propranolol formulations. Propranolol cream (hydrophilic cream, 1, 3, and 5%) and gels (carboxyvinyl polymer, hydroxypropyl methylcellulose, gellan gum, 1%) were prepared. The in vitro skin permeability of these formulations was assessed using Franz-type diffusion cells. The pharmaceutical profiles, including propranolol content, pH, and ductility, of the propranolol creams were evaluated. For the stability test, similar pharmaceutical evaluations were performed after the creams were stored at 25 °C and 56% relative humidity for 3 months. We examined three patients treated with propranolol cream to investigate the clinical course of IH and adverse events after the propranolol cream was applied for 5–12 months. In the in vitro skin permeability assay, topical propranolol formulations made of hydrophilic cream and gellan gum permeated the most. The amount of propranolol that permeated increased with propranolol concentration. After storage for 3 months, no substantial changes were observed in any pharmaceutical profile. The IHs were discolored in all patients. Tumor size also decreased in some patients. Furthermore, no adverse events caused by propranolol cream were observed during application. In conclusion, propranolol cream can be prepared as a hospital formulation with adequate quality. Topical propranolol therapy is effective in reducing the incidence of systemic ADRs.
- 1 April 2022
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 70 (4) , 277-282
Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream
Propranolol is used as the first-line treatment for infantile hemangiomas (IHs). As oral formulations can cause systemic adverse drug reactions (ADRs), we prepared topical propranolol formulations and evaluated their pharmaceutical profiles. We also present three cases of pediatric patients with IHs who were treated with the propranolol formulations. Propranolol cream (hydrophilic cream, 1, 3, and 5%) and gels (carboxyvinyl polymer, hydroxypropyl methylcellulose, gellan gum, 1%) were prepared. The in vitro skin permeability of these formulations was assessed using Franz-type diffusion cells. The pharmaceutical profiles, including propranolol content, pH, and ductility, of the propranolol creams were evaluated. For the stability test, similar pharmaceutical evaluations were performed after the creams were stored at 25 °C and 56% relative humidity for 3 months. We examined three patients treated with propranolol cream to investigate the clinical course of IH and adverse events after the propranolol cream was applied for 5–12 months. In the in vitro skin permeability assay, topical propranolol formulations made of hydrophilic cream and gellan gum permeated the most. The amount of propranolol that permeated increased with propranolol concentration. After storage for 3 months, no substantial changes were observed in any pharmaceutical profile. The IHs were discolored in all patients. Tumor size also decreased in some patients. Furthermore, no adverse events caused by propranolol cream were observed during application. In conclusion, propranolol cream can be prepared as a hospital formulation with adequate quality. Topical propranolol therapy is effective in reducing the incidence of systemic ADRs.
- Open Access
- 1 February 2019
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 67 (2) , 112-119
Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability
Orally disintegrating tablets (ODTs), which are administered without water, are beneficial for elderly patients and patients with dysphagia. Masking the unpleasant taste of a drug is an important factor associated with adherence of patients consuming ODTs. We prepared cocoa powder-containing ODTs of bitter-tasting rebamipide (rebamipide chocolet) and evaluated their clinical palatability. We prepared rebamipide ODTs by adding a sweetener and 0, 2.5, 5, and 10% cocoa powder (Ch0-ODTs, Ch2.5-ODTs, Ch5-ODTs, and Ch10-ODTs, respectively). Rebamipide ODTs without cocoa powder and sweetener were used as controls (Cont-ODTs). We performed a gustatory sensation test in 30 healthy adult volunteers. We used the 100-mm visual analog scale (VAS) to evaluate bitterness, sweetness, scent, and overall palatability of the ODTs. The acceptability of each ODT was evaluated on a 5-point scale. Compared to Cont-ODTs, Ch0-ODTs showed no significant improvement in the VAS score for bitterness, scent, and overall palatability during disintegration. However, compared to Cont-ODTs, Ch2.5-ODTs, Ch5-ODTs, and Ch10-ODTs showed an improvement in all items evaluated using the VAS. In particular, Ch2.5-ODTs showed a significant improvement compared to the Cont-ODTs in the VAS score of all items. Evaluation on a 5-point scale indicated that Ch2.5-ODTs and Ch10-ODTs had the highest acceptability. We prepared rebamipide chocolet with excellent palatability properties, which could not be achieved using a sweetener alone, by using the combination of a sweetener and cocoa powder as a new agent for masking bitterness. Our results indicate that cocoa powder may be used as a taste-masking agent in ODTs.
- 1 February 2019
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 67 (2) , 112-119
Open AccessPreparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability
Orally disintegrating tablets (ODTs), which are administered without water, are beneficial for elderly patients and patients with dysphagia. Masking the unpleasant taste of a drug is an important factor associated with adherence of patients consuming ODTs. We prepared cocoa powder-containing ODTs of bitter-tasting rebamipide (rebamipide chocolet) and evaluated their clinical palatability. We prepared rebamipide ODTs by adding a sweetener and 0, 2.5, 5, and 10% cocoa powder (Ch0-ODTs, Ch2.5-ODTs, Ch5-ODTs, and Ch10-ODTs, respectively). Rebamipide ODTs without cocoa powder and sweetener were used as controls (Cont-ODTs). We performed a gustatory sensation test in 30 healthy adult volunteers. We used the 100-mm visual analog scale (VAS) to evaluate bitterness, sweetness, scent, and overall palatability of the ODTs. The acceptability of each ODT was evaluated on a 5-point scale. Compared to Cont-ODTs, Ch0-ODTs showed no significant improvement in the VAS score for bitterness, scent, and overall palatability during disintegration. However, compared to Cont-ODTs, Ch2.5-ODTs, Ch5-ODTs, and Ch10-ODTs showed an improvement in all items evaluated using the VAS. In particular, Ch2.5-ODTs showed a significant improvement compared to the Cont-ODTs in the VAS score of all items. Evaluation on a 5-point scale indicated that Ch2.5-ODTs and Ch10-ODTs had the highest acceptability. We prepared rebamipide chocolet with excellent palatability properties, which could not be achieved using a sweetener alone, by using the combination of a sweetener and cocoa powder as a new agent for masking bitterness. Our results indicate that cocoa powder may be used as a taste-masking agent in ODTs.